Concentration-EEG effect relationship of propofol in rats

被引:37
作者
Dutta, S
Matsumoto, Y
Gothgen, NU
Ebling, WF
机构
[1] SHOWA COLL PHARMACEUT SCI,DEPT PHARMACEUT,MACHIDA,TOKYO 194,JAPAN
[2] SUNY BUFFALO,DEPT PHARMACEUT,AMHERST,NY 14260
[3] DUPONT CO INC,STINE HASKELL RES CTR,DUPONT MERCK PHARMACEUT DRUG METAB & PHARMACEUT S,NEWARK,DE 19714
关键词
D O I
10.1021/js960247n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Propofol is a unique highly lipid-soluble anesthetic that is formulated in a fat emulsion (Diprivan) for intravenous (iv) use. It has the desirable properties of rapid onset and offset of effect following rapid iv administration and minimal accumulation on long-term administration. Based on physicochemical properties and preliminary brain solubility data, propofol should have an extended effect-site turnover and a resulting prolonged effect. However, a preliminary study in humans has reported a rapid blood-brain equilibration half-time (T-1/2 k(E0)) Of only 2.9 min. We used a chronically instrumented rat model to examine the unique disposition and electroencephalographic (EEG) pharmacodynamics of propofol. Although the pharmacokinetics were variable, there was low interindividual variability in the concentration-EEG effect relationship. The duration of EEG sleep was 26 (+/-44% CV) min following 11-15 mg/kg doses of propofol. The T-1/2 k(E0) was 1.7 (+/-32%) min. Apparent effect-site concentrations of 0.5-1 mu g/mL were required to maintain sleep in rats. Like other general anesthetics, the concentration-EEG effect relationship of propofol is biphasic. At a propofol concentration of 0.6 (+/-35%) mu g/mL, the number of EEG waves/s was maximal at 175% of baseline awake state. Further increases in the concentration of propofol depressed EEG activity until complete suppression occurred at 7 (+/-22%) mu g/mL.
引用
收藏
页码:37 / 43
页数:7
相关论文
共 28 条
[1]  
BUHRER M, 1992, ANESTHESIOLOGY, V77, P226
[2]  
DANHOF M, 1984, J PHARMACOL EXP THER, V229, P44
[3]   PROGRAM PACKAGE FOR SIMULATION AND PARAMETER-ESTIMATION IN PHARMACOKINETIC SYSTEMS [J].
DARGENIO, DZ ;
SCHUMITZKY, A .
COMPUTER PROGRAMS IN BIOMEDICINE, 1979, 9 (02) :115-134
[4]   PROPOFOL - A REVIEW OF THE PHARMACOLOGY AND APPLICATIONS OF AN INTRAVENOUS ANESTHETIC AGENT [J].
DEEGAN, RJ .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1992, 304 (01) :45-49
[5]   High-performance liquid chromatographic assay of propofol in human and rat plasma and fourteen rat tissues using electrochemical detection [J].
Dowrie, RH ;
Ebling, WF ;
Mandema, JW ;
Stanski, DR .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 678 (02) :279-288
[6]   Parameter estimability of biphasic response models [J].
Dutta, S ;
Ebling, WF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (01) :44-51
[7]   FROM PIECEWISE TO FULL PHYSIOLOGICAL PHARMACOKINETIC MODELING - APPLIED TO THIOPENTAL DISPOSITION IN THE RAT [J].
EBLING, WF ;
WADA, DR ;
STANSKI, DR .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1994, 22 (04) :259-292
[8]   PHARMACODYNAMIC CHARACTERIZATION OF THE ELECTROENCEPHALOGRAPHIC EFFECTS OF THIOPENTAL IN RATS [J].
EBLING, WF ;
DANHOF, M ;
STANSKI, DR .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (02) :123-143
[9]   PROPOFOL INFUSION AND THE SUPPRESSION OF CONSCIOUSNESS - THE EEG AND DOSE REQUIREMENTS [J].
FORREST, FC ;
TOOLEY, MA ;
SAUNDERS, PR ;
PRYSROBERTS, C .
BRITISH JOURNAL OF ANAESTHESIA, 1994, 72 (01) :35-41
[10]  
Gibaldi M. P., 1982, PHARMACOKINETICS